There was some good news in the clinical sphere for Gilead Sciences ( GILD 2.74%) on Thursday, and this drove its stock price ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

Gilead Sciences Inc.’s twice-yearly HIV prevention shot prevented almost all HIV cases in a large trial in men and transgender people, a result that will allow the company to file for approval by end ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...

Gilead's news was that its second phase 3 trial ... drug reduced new infections with the disease by 96% when compared to background HIV incidence. Lenacapavir, which is only administered twice ...